Emerging treatments in type 2 diabetes: focus on canagliflozin.
about
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.rich in 3, 5-/4, 5-dicaffeoylquinic acid and chlorogenic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice
P2860
Emerging treatments in type 2 diabetes: focus on canagliflozin.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@ast
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@en
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@nl
type
label
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@ast
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@en
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@nl
prefLabel
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@ast
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@en
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@nl
P2093
P2860
P356
P1476
Emerging treatments in type 2 diabetes: focus on canagliflozin.
@en
P2093
Dariusz A Kosior
Marek Rosiak
Susanna Grzeszczak
P2860
P304
P356
10.2147/TCRM.S39145
P577
2014-08-21T00:00:00Z